57 completed, 20 unknown, 15 terminated, 14 recruiting. 124 Phase 2, 21 Phase 3, 15 Phase 1.
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis | Phase 2 | Not yet recruiting | University College, London | 445 | 2026-12-01 | 2026-09-11 |
| Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID) - Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM) | Phase 2 | Not yet recruiting | Amckaus PTY LTD. | 56 | 2026-10-01 | 2026-06-30 |
| Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression Vericiguat (BAY1021189), Placebo - Calcific Aortic Valve Disease, AORTIC VALVE DISEASES | Phase 2 | Recruiting | West China Hospital | 238 | 2026-09-24 | 2026-09-25 |
| Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot Valsartan, Placebo - Atrial Functional Mitral Regurgitation | Phase 2 / Phase 3 | Recruiting | Jonathan Beaudoin | 50 | 2026-07-13 | 2026-08-20 |
| Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy LX2006, Usual Care - Friedreich Ataxia, Cardiomyopathy, Secondary | Phase 2 | Recruiting | Lexeo Therapeutics | 26 | 2026-06-25 | 2026-09-02 |
| Ademetionine in Obstructive Hypertrophic Cardiomyopathy Ademetionine 1,4-Butanedisulfonate, Placebo - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 2 | Recruiting | China National Center for Cardiovascular Diseases | 44 | 2026-01-01 | 2026-03-20 |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases Injection of 68Ga-NI-FAPI - Tumor, Cardiovascular Diseases | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-12-17 | 2026-03-11 |
| A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Ninerafaxstat 200mg MR, Placebo - Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Recruiting | Imbria Pharmaceuticals, Inc. | 165 | 2025-10-06 | 2026-10-26 |
| A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy HRS-1893 Tablet - Hypertrophic Cardiomyopathy | Phase 2 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 300 | 2025-07-04 | 2025-09-10 |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study Ataciguat, Placebo - Moderate Aortic Valve Stenosis | Phase 2 / Phase 3 | Recruiting | Kardigan, Inc. | 1276 | 2025-06-27 | 2026-07-06 |
| A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy HRS-1893 - Obstructive Hypertrophic Cardiomyopathy | Phase 2 | Active not recruiting | Shandong Suncadia Medicine Co., Ltd. | 42 | 2024-08-11 | 2025-07-16 |
| The Role of SGLT2i in Management of Moderate AS Empagliflozin 10 MG - Moderate Aortic Valve Stenosis | Phase 2 / Phase 3 | Completed | University of East Anglia | 104 | 2024-05-30 | 2026-07-28 |
| A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) EDG-7500 - Hypertrophic Cardiomyopathy | Phase 2 | Active not recruiting | Edgewise Therapeutics, Inc. | 79 | 2024-04-11 | 2026-07-31 |
| Clemastine Treatment in Individuals With Williams Syndrome Open Label Clemastine with a blinded randomize withdrawal - Williams Syndrome | Phase 2 | Active not recruiting | Sheba Medical Center | 30 | 2024-04-01 | 2026-03-06 |
| Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome Clemastine Fumarate Tablets, corn starch tablets - Williams Syndrome, Child | Phase 2 | Completed | Qilu Hospital of Shandong University | 28 | 2024-03-20 | 2026-03-19 |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis Pelacarsen (TQJ230) 80mg, Matching placebo - Aortic Stenosis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 502 | 2024-03-07 | 2026-06-23 |
| A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease RP-A501 - Danon Disease | Phase 2 | Recruiting | Rocket Pharmaceuticals Inc. | 18 | 2023-09-05 | 2026-10-06 |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM TN-201 - Hypertrophic Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Tenaya Therapeutics | 30 | 2023-08-10 | 2026-03-19 |
| Effects of Pioglitazone in Calcific Aortic Valve Disease Drug: Pioglitazone Oral Tablet, Placebo - Calcification of Aortic Valve, Aortic Valve Stenosis | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 100 | 2023-07-01 | 2023-05-25 |
| Folic Acid Supplementation in Calcific Aortic Valve Disease Folic Acid Oral Tablet, Placebo - Calcification of Aortic Valve, Aortic Valve Stenosis | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 100 | 2023-07-01 | 2023-05-17 |
Showing 20 of 124. Sign in to see all of them.
Cardiomyopathy, Hypertrophic (41) · Aortic Valve Stenosis (29) · Mitral Valve Insufficiency (17) · Coronary Artery Disease (11) · Heart Failure (10) · Hypertrophy, Left Ventricular (6) · Aortic Valve Disease (5) · Atrial Fibrillation (5) · Cardiomyopathies (5) · Heart Diseases (5) · Myocardial Ischemia (5) · Cardiovascular Diseases (4) · Aortic Valve, Calcification of (3) · Cardiomyopathy, Hypertrophic, Familial (3)
Cardiovascular Diseases (120) · Heart Diseases (119) · Aortic Valve Disease (74) · Aortic Valve Stenosis (44) · Aortic Stenosis, Subvalvular (41) · Cardiomyopathies (38) · Pathological Conditions, Signs and Symptoms (32) · Ventricular Outflow Obstruction (30) · Vascular Diseases (23) · Pathologic Processes (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Myocardial Ischemia (13) · Pathological Conditions, Anatomical (13) · Arterial Occlusive Diseases (11)
Warfarin (5) · Mitral Valve Annuloplasty (4) · Perhexiline (4) · Valsartan (4) · sacubitril and valsartan sodium hydrate drug combination (4) · MYK-461 (3) · Rivaroxaban (3) · 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide (2) · Bosentan (2) · Losartan (2) · Metoprolol (2) · Saline Solution (2) · Vitamin K 2 (2) · Alendronate (1) · Aminolevulinic Acid (1)
National Heart, Lung, and Blood Institute (NHLBI) (6) · Bristol-Myers Squibb (3) · Viacor (3) · Xijing Hospital (3) · China National Center for Cardiovascular Diseases (2) · Copenhagen University Hospital, Rigshospitalet (2) · Cytokinetics (2) · Edwards Lifesciences (2) · Novartis Pharmaceuticals (2) · Ottawa Heart Institute Research Corporation (2) · Seoul National University Hospital (2) · Shandong Suncadia Medicine Co., Ltd. (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · University College, London (2) · University Hospital Birmingham (2)
United States (45) · Germany (18) · United Kingdom (18) · Canada (15) · France (12) · Netherlands (12) · China (11) · Denmark (11) · Italy (11) · Spain (9) · Czechia (6) · South Korea (6) · Switzerland (6) · Belgium (5) · Israel (5)
Annetine C. Gelijns, Ph.D. (2) · Patrick O'Gara, MD (2) · Rainer Hoffmann, MD (2) · Timothy Gardner, MD (2) · Amy Sehnert, MD (1) · Anders H Hebert, MD (1) · Andre Duraes, PhD (1) · Ann-Dorthe Zwisler, MD, Ph.d. (1) · Arash Yavari, DPhil MRCP (1) · Barry Greenberg, MD (1) · Bas Kietselaer, M.D. PhD (1)
PMID 24621999, PMID 25533774, PMID 42592935, PMID 12957437, PMID 14667752, PMID 18403758, PMID 19074594, PMID 19679246, PMID 20837938, PMID 20921440, PMID 21126639, PMID 21168015, PMID 21382896, PMID 21422390, PMID 21492763, PMID 22075468, PMID 22084331, PMID 22797672, PMID 22818065, PMID 22932717, PMID 23633132, PMID 23663658, PMID 23718572, PMID 23782510, PMID 23991661, PMID 24245543, PMID 24361242, PMID 24674997, PMID 24824357, PMID 24837794, PMID 25176015, PMID 25446057, PMID 25500293, PMID 25533966, PMID 25791027, PMID 25853744, PMID 25882205, PMID 25887433, PMID 26227196, PMID 26550689, PMID 26661322, PMID 26874390, PMID 26898633, PMID 27492941, PMID 27590665, PMID 27733431, PMID 27777294, PMID 27940009, PMID 28306757, PMID 28547861
2019 (3), U01HL088942 (2), 2015 (1), 2018 (1), 2023 (1), 2025 (1), 595 (1), 5UH3HL148693 (1), K23HL078901 (1), P50HL112349 (1)